Oric Pharmaceuticals, Inc. ORIC
Oric Pharmaceuticals, Inc. (Nasdaq: ORIC) is an oncology drug developer. Its lead program, rinzimetostat (ORIC-944), is in Phase 3 for metastatic castration-resistant prostate cancer (post-abiraterone), in combination with darolutamide. Its next catalyst on record is enozertinib: Phase 1b data in 1L NSCLC EGFR exon 20 (monotherapy and with SC amivantamab) and 1L EGFR atypical mutations (monotherapy) (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: enozertinib — Phase 1b data in 1L NSCLC EGFR exon 20 (monotherapy and with SC amivantamab) and 1L EGFR atypical mutations (monotherapy) (H2 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| rinzimetostat + darolutamide (Himalayas-1, Phase 3) | post-abiraterone mCRPC | small molecule | Phase 3 |
| rinzimetostat + apalutamide / darolutamide (Phase 1b dose optimization) | mCRPC | small molecule | Phase 1 |
| enozertinib (ORIC-114; Phase 1b) | NSCLC with EGFR exon 20 insertion and atypical (PACC) mutations | small molecule | Phase 1 |
Recent results and decisions
- Oct 23, 2026positive Enozertinib Phase 1b trial in 1L EGFR atypical NSCLC achieved 84% confirmed systemic ORR, 70% confirmed CNS ORR, and 88% 6-month landmark PFS.
Enozertinib demonstrated meaningful systemic activity, including: 84% (21 of 25) confirmed systemic ORR by investigator.
Filing - Aug 3, 2026started Himalayas-1 global Phase 3 (about 600 patients, 1:1 vs physician's choice AR inhibitor or docetaxel; primary endpoint rPFS) initiated.
Finalized the trial protocol and initiated the Himalayas-1 global Phase 3 registrational trial following End-of-Phase 1 interactions with the FDA and other global health authorities.
Filing - Mar 31, 2026positive 400 mg QD plus darolutamide: landmark rPFS 93%/84%/84% at 3/4/5 months, PSA50 33% confirmed, one Grade 3 TRAE; selected as Phase 3 dose.
Rinzimetostat + ARi safety profile compatible with long-term dosing, with the majority of AEs Grade 1, and no Grade 4/5 events
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.